Comprehensive review of targeted therapy for colorectal cancer
YH **e, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification
K Yoshida, K Yamaguchi, N Okumura, T Tanahashi… - Gastric cancer, 2016 - Springer
Conversion therapy for gastric cancer (GC) has been the subject of much recent attention. It
is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors …
is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors …
Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2021 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
There is a clear and unmet clinical need for biomarkers to predict responsiveness to
chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor …
chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor …
Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, L Cederquist, E Chan… - Journal of the National …, 2017 - jnccn.org
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …
therapy in metastatic disease. Considerations for treatment selection among 32 different …
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line
oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or …
oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or …
Cancer metabolism: current understanding and therapies
Dysregulation of cancer cell metabolism contributes to abnormal cell growth, the biological
end point of cancer. We review here numerous affected oncogenes and metabolic pathways …
end point of cancer. We review here numerous affected oncogenes and metabolic pathways …
Capecitabine: a review
CM Walko, C Lindley - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Fluorouracil (FU) is an antimetabolite with activity against numerous types
of neoplasms, including those of the breast, esophagus, larynx, and gastrointestinal and …
of neoplasms, including those of the breast, esophagus, larynx, and gastrointestinal and …
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Purpose To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to
fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic …
fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic …
Oxaliplatin: a review in the era of molecularly targeted therapy
T Alcindor, N Beauger - Current oncology, 2011 - mdpi.com
Objective: To review preclinical and clinical data for oxaliplatin in the current context of
molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and …
molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and …